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Microdosimetric Modeling of 
Biological Effectiveness for 
Boron Neutron Capture Therapy 
Considering Intra- and Intercellular 
Heterogeneity in 10B Distribution
Tatsuhiko Sato1, Shin-ichiro Masunaga2, Hiroaki Kumada3 & Nobuyuki Hamada4
We here propose a new model for estimating the biological effectiveness for boron neutron capture 
therapy (BNCT) considering intra- and intercellular heterogeneity in 10B distribution. The new model 
was developed from our previously established stochastic microdosimetric kinetic model that 
determines the surviving fraction of cells irradiated with any radiations. In the model, the probability 
density of the absorbed doses in microscopic scales is the fundamental physical index for characterizing 
the radiation fields. A new computational method was established to determine the probability density 
for application to BNCT using the Particle and Heavy Ion Transport code System PHITS. The parameters 
used in the model were determined from the measured surviving fraction of tumor cells administrated 
with two kinds of 10B compounds. The model quantitatively highlighted the indispensable need to 
consider the synergetic effect and the dose dependence of the biological effectiveness in the estimate 
of the therapeutic effect of BNCT. The model can predict the biological effectiveness of newly developed 
10B compounds based on their intra- and intercellular distributions, and thus, it can play important roles 
not only in treatment planning but also in drug discovery research for future BNCT.
Neutron capture therapy using the 10B(n, α) 7Li reaction, BNCT, is one of the most effective therapeutic modal-
ities for treating locally invasive malignant tumors thanks to the large neutron-capture cross sections of 10B as 
well as short ranges of their secondary particles. Upon this reaction, 1.77 MeV α particle and 1.02 MeV 7Li ion are 
emitted at the branching ratio of 6.3%, while 1.47 MeV α particle, 0.84 MeV 7Li ion, and 0.478 MeV photon are 
produced in the remaining 93.7% cases. In addition, 0.54 MeV protons emitted from the 14N(n, p)14C reaction, 
recoil protons produced by the 1H(n,n)p reaction, photons generated by the 1H(n,γ)2H reaction, and contamina-
tion photons in the neutron beam also contribute to energy deposition during BNCT. In the treatment planning 
of BNCT, the absorbed doses deposited by 10B(n, α)7Li, 14N(n, p)14C, 1H(n, n)p, and photons are separately cal-
culated1,2, which are referred hereinafter to as boron, nitrogen, hydrogen, and photon components, respectively.
Low energy particles with high linear energy transfer (LET) are dominant contributors to the absorbed doses, 
except for the photon component. Thus, estimate of their relative biological effectiveness (RBE) is indispensable 
for the maximal therapeutic efficacy to tumors while sparing normal tissues. Several models have been proposed 
for evaluating the RBE of high LET charged particles relevant to BNCT3–6. However, the therapeutic efficacy 
depends not only on the RBE but also on the intra- and intercellular heterogeneity of 10B distribution. For exam-
ple, 10B-boronphenylalanine (BPA: C9H12BNO4) is more effective for tumor cell inactivation than 10B-sodium 
borocaptate (BSH: Na2B12H11SH) at the same 10B concentration owing to cell permeability of BPA7. The concept of 
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the compound biological effectiveness (CBE)8,9 was then introduced to consider this effect in the BNCT treatment 
planning. The stochastic nature of the intercellular 10B distribution is also expected to influence the therapeutic 
efficacy10 because the surviving fraction (SF) of a cell population generally becomes larger with increasing hetero-
geneity of absorbed dose in each cell nucleus, particularly at higher doses11 Furthermore, the sum of the absorbed 
dose weighted by fixed RBE or CBE (hereafter, RBE-weighted dose) of each component, which is currently evalu-
ated in the BNCT treatment planning, may not be an adequate index for representing its therapeutic effect, since 
RBE and CBE vary with the absorbed dose, and the synergistic effect exists in the radiation fields composed by 
different radiations12,13. Thus, the photon dose giving the same therapeutic effect (hereafter, photon-isoeffective 
dose) was proposed for use in the BNCT treatment planning14,15.
Here, we set out to develop a new model for estimating RBE and CBE as well as photon-isoeffective doses 
of BNCT considering the intra- and intercellular heterogeneity in 10B distribution. It is based on the stochastic 
microdosimetric kinetic (SMK) model11, which was developed from the microdosimetric kinetic (MK) model 
proposed by Hawkins16. These models can estimate the cellular SF, not from the profiles of radiation imparting 
energy such as LET, but from the dose distribution at microscopic sites in the cell nucleus, so-called domains. 
These models thus consider the synergistic effect intrinsically. In our developed model, dose distributions in 
domains are calculated by the microdosimetric function17–19 implemented in the Particle and Heavy Ion Transport 
code System PHITS20, considering the intracellular 10B distributions. In addition, the SMK model was improved 
to be capable of taking the dose rate effect into account. An advantage of the SMK model over the original MK 
model is that while the former can fully consider the stochastic nature of the absorbed dose in each cell nucleus, 
the latter approximates the dose by their mean value. This feature is particularly important when it is applied to 
BNCT because the greater heterogeneity of the absorbed dose in each cell nucleus are expected for BNCT than for 
other radiotherapeutic modalities, due to the stochastic nature of the intercellular 10B distribution21.
Four parameters that express cellular characteristics must be evaluated in the developed model. In this study, 
their numerical values were determined by the least-square (LSq) fitting of the SF of tumor cells, which we pre-
viously determined in vivo/in vitro experiments of mice exposed to reactor neutron beam with concomitant BPA 
or BSH treatment at various concentrations22. Thus, this paper focuses on the analysis of the therapeutic effect of 
BNCT, and does not discuss about normal tissue complications. The details of the calculation procedures in the 
developed model are shown below, and the calculated SF is compared with the corresponding measured data. 
The influence of the intra- and intercellular heterogeneity in 10B distribution on the SF, and the difference in the 
RBE-weighted and photon-isoeffective doses are discussed.
Methods
Principle of the SMK and MK models. The MK model is one of the most successful models to explain the 
biological effectiveness for the cellular SF. It mathematically interprets the linear-quadratic (LQ) relation of the SF 
based on the theory of dual radiation action23. In the model, the following six basic assumptions were made: (i) 
a cell nucleus can be divided into multiple domains; (ii) radiation exposure produces two types of DNA damage 
named lethal and sublethal lesions in cell nuclei; (iii) the number of lethal and sublethal lesions produced in a 
domain is proportional to the specific energy, z, in the domain; (iv) a sublethal lesion is to be repaired, or con-
verted into a lethal lesion via spontaneous transformation or interaction with another sublethal lesion created in 
the same domain; (v) a domain is to be considered inactivated when an intra-domain lethal lesion is formed; and 
(vi) a cell is to be considered inactivated when an intranuclear domain is inactivated. Note that the specific energy 
z indicates the energy deposited per mass at a microscopic site. z is a stochastic quantity and therefore intrinsi-
cally different from the absorbed dose, albeit with the same unit. The definition of specific energy as well as other 
microdosimetric quantities is summarized in International Commission on Radiation Units and Measurements 
(ICRU) Report 3624.
Based on these assumptions, the SF of a single cell with its nucleus specific energy zn, S z( )C n , can be calculated 
by
α β β= − + −S z z z z( ) exp[ ( ) ], (1)DC n 0 0 d, n 0 n
2
where z Dd,  denotes the dose-mean value of specific energy in domain, zd, per event written as
∫
∫
=
∞
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z f z z
z f z z
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( )d
,
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d,D
0 d
2
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0 d d,1 d d
where fd,1(zd) is the probability density (PD) of zd per event. Note that the term of “event” denotes a single hit of 
radiation in microdosimetry. The parameters α0 in Eq. (1) expresses the inactivation sensitivity of domains to 
lethal lesions, and β0 represents the interaction probability of two sublethal lesions created in the same domain. 
In addition to α0 and β0, the domain radius, rd, are the free parameters representing the characteristics of the cell 
type in the MK model. The numerical values of these parameters are independent of the radiation imparting the 
energy.
Considering the stochastic nature of zn, the SF of a cell group irradiated with the mean cell-nucleus dose zn, 
S z( )G n , can be estimated by
∫=
∞
S z S z f z z z( ) ( ) ( , )d , (3)G n 0 C n n n n n
where f z z( , )n n n  is the PD of zn for the mean cell-nucleus dose zn, as follows:
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In the original MK model, S z( )G n  is simply approximated by Sn(zn) by ignoring the stochastic nature of zn, i.e., 
substituting the Dirac’s delta-function δ z( )n  for f z z( , )n n n  in Eq. (3). In contrast, Eq. (3) is numerically solved in 
the SMK model because our previous study revealed that the consideration of the stochastic nature of zn is of great 
importance in estimating SF following high-dose, high-LET irradiation11. Since the number of events contribut-
ing to the energy deposition is expected to follow a Poisson distribution, f z z( , )n n n  can be calculated by
∑
λ
=
λ−
f z z z e
k
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!
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(5)k
k z
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n
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n
where fn,k(zn) is the PD of zn per k events, which can be determined from fn,1(zn) and fn,k−1(zn) using the convolu-
tion method as written by
∫= − .−f z f z f z z z( ) ( ) ( )d (6)k
z
kn, n 0 n,1 n, 1
n
n
The expected value of the Poisson distribution, λ z( )n , can be estimated by
λ =z z
z
( ) ,
(7)
n
n
n,F
where zn,F is the frequency-mean zn per event, which can be calculated by
∫= .
∞
z z f z z( )d (8)n,F 0 n n,1 n n
Eqs (1–8) can be numerically solved by determining fd,1(zd) and fn,1(zn), and thus, their evaluations are pivotal 
in estimating SF based on the SMK model. The calculation procedures of fd,1(zd) and fn,1(zn) were established 
based on the microdosimetric and LET-estimator functions, respectively, implemented in PHITS, assuming that 
all radiations can penetrate the targets. However, this assumption is not valid for estimating fn,1(zn) in the radi-
ation fields of BNCT due to the short ranges of secondary particles produced by neutron capture reactions. In 
addition, the intracellular heterogeneity of 10B distribution influences both fn,1(zn) and fd,1(zd). Accordingly, a 
new method was developed here for calculating fd,1(zd) and fn,1(zn) for BNCT as described in the next subsection.
In our previous study, the overkill effect following high LET irradiation was considered in the SMK model by 
introducing a free parameter z0 called “saturation parameter”. In a domain with z over z0, the numbers of lethal 
and sublethal lesions produced in the domain are assumed to be saturated, and not proportional to z. However, 
the model developed here does not need this parameter because the overkill effect was not observed in the meas-
ured SF used for the parameter determination in this study, i.e. the higher z0 values always provided the better 
fitting results. This is why the double stochastic microdosimetric kinetic (DSMK) model11, which can handle the 
saturation correction more precisely but with longer computational time, was not employed in this study. Taken 
together, the SMK and DSMK models have a function to deal with the nontargeted effects25, but this function is 
not used in this study because the nontargeted effects play only a negligible role in cell inactivation at high-dose 
irradiation where estimation of the therapeutic effect is important.
On the other hand, we improved the SMK model to be capable of considering the dose rate effect, which is 
very important in the estimate of the therapeutic effect of BNCT due to its relatively longer irradiation time in 
comparison to other radiotherapeutic modalities. Considering the decrease of sublethal lesions during irradia-
tion, Eq. (1) should be replaced by
α β β= − + −S z z z G z( ) exp[ ( ) ], (9)C n 0 0 d,D n 0 n
2
where G is the correction factor of the quadratic coefficient of the LQ relationship26,27. The numerical value of G 
can be approximated by
γ
γ γ= − − +G
T
T T2
( )
[exp( ) 1 ],
(10)0
2 0 0
where T is the irradiation time, and γ0 is the first order rate constant of repair and spontaneous transformation of 
sublethal lesions. In this study, γ0 is regarded as a free parameter.
Calculation of PD of zd and zn considering intracellular 10B distribution. In order to estimate fd,1(zd) 
and fn,1(zn) in the radiation fields of BNCT, we performed the particle transport simulation in a three-dimensional 
cellular matrix using PHITS version 2.88. The simulation procedure is similar to that conducted for evaluating 
the effect of internal exposure28. Figure 1 shows a cross-sectional view of our modeled cellular matrix depicted 
by PHITS. Cells and their nuclei were assumed to be spheres with a radius of 5 μm and 3 μm, respectively, which 
were the approximated values according to the fluorescence microscopy of SCC VII squamous cell carcinomas 
used in our previously study22. The distance between the centers of a cell and its nucleus is fixed at 1.5 μm, which 
corresponds to its mean value calculated under the assumption that a cell nucleus is randomly located in the 
cytoplasm. They were placed in an 11 × 11 × 11 lattice structure, yielding 1,331 cells in the system. The density of 
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cells including their nucleus and extracellular space was set to 1 g/cm3, of which composition was assumed to be 
the same as that used in the dose evaluation of the experimental data, i.e., H (11.1%), C (12.6%), N (2.1%), and 
O (74.2%) by weight.
In the PHITS simulation for determining fd,1(zd) and fn,1(zn) for the boron component, secondary charged par-
ticles emitted from neutron capture reaction of 10B, i.e., an α particle and a 7Li ion, were generated to the opposite 
directions as a Monte Carlo history, using the correlation source generation function of PHITS. The branching 
ratio of the reaction was considered, though the generation of 0.478 MeV secondary photons was ignored in the 
simulation because their energy depositions were categorized as the photon component. The PHITS simulations 
were carried out four times by changing the source localizations, assuming the uniform distribution of 10B in the 
cell nucleus, cytoplasm, extracellular space, or at a boundary between cytoplasm and extracellular space (here-
after, cell surface) of the central lattice. The PD of zn per event, fn,1(zn), was estimated by calculating the energy 
deposited in each cell nucleus per Monte Carlo history. In addition, the PD of zd per event, fd,1(zd), in cell nuclei 
was calculated using the microdosimetric function in PHITS by changing the domain radii from 0.1 to 0.3 μm 
by 0.01 μm step. For each condition, Monte Carlo history was set to 1 million, and the PHITS simulation took 
approximately 15 minutes using a Linux system with 32 CPU cores. Note that the microdosimetric function was 
developed by fitting the results of track-structure simulation, and thus, it can analytically determine the PD of 
microscopic sites down to the nanometer scales, considering the dispersion of deposition energies due to the 
production of δ-rays. Therefore, each domain in cell nucleus was not explicitly specified in the geometry of the 
PHITS simulation, as shown in Fig. 1.
Considering the intracellular heterogeneity of the 10B distribution, fd,1(zd) for the entire boron component, 
f z( )d,1
B
d , can be obtained by averaging the data for each localized source, f z( )d,1
B,n
d , f z( )d,1
B,c
d , f z( )d,1
B,s
d , and f z( )d,1
B,e
d , 
weighted by their 10B fractions as written by
=
+ + +
+ + +
f z
N f z N f z N f z N f z
N N N N
( )
( ) ( ) ( ) ( )
,
(11)
d d
d,1
B
d
n d,1
B,n
d c ,1
B,c
d s ,1
B,s
d e d,1
B,e
d
n c s e
where N is the relative number of 10B distributed in each cell compartment, and their subscripts (i.e., “n”, “c”, “s” 
and “e”) indicate the data for cell nucleus, cytoplasm, cell surface, and extracellular space, respectively. The total 
number of 10B in the entire region including extracellular space is normalized to 1.0, i.e., Nn + Nc + Ns + Ne = 1.0. 
For BPA, we set Nn = Ns = 0 because BPA enters cells through amino acid transporters21,29, and is assumed here to 
distribute in the cytoplasm, but not in the cell nucleus. For BSH, we set Nn = Nc = 0 because BSH does not pass 
through the cell membrane30. The ratios between the 10B concentrations in intra- and extracellular regions were 
taken from the experimental data for malignant cells, which were approximately 3.2 for BPA and 0.86 for BSH31. 
Then, Nc and Ne for BPA were evaluated to be 0.78 and 0.22, respectively, and Ns and Ne for BSH were to be 0.48 
and 0.52, respectively, considering the volume ratio between intra- and extracellular regions in our model. The 
PD of zn for the entire boron component, f z( )Bn,1 n , can also be determined from an equation similar to Eq. (11) by 
replacing fd,1(zd) by fn,1(zn).
To calculate fd,1(zd) and fn,1(zn) for other dose components, their source terms must be evaluated before con-
ducting the microscopic PHITS simulation because the energy spectra of secondary charged particles depend 
on the irradiation conditions such as the incident neutron spectrum particularly for the hydrogen component. 
We therefore performed the macroscopic PHITS simulation to determine the source terms by reproducing the 
experimental irradiation conditions used in our previous study21. In the simulation, a cubic-shaped tumor with 
volume of 1 cm3 was irradiated with neutron beam in the OO-0000-F mode of Kyoto University Research Reactor 
(KUR)32, and spectra of produced charged particles including recoil nuclei were scored for each mother nucleus 
using the event generator mode33. The charged particles emitted only from the 14N(n,p)14C reaction were regarded 
as the nitrogen component, while others were categorized as the hydrogen component. Thus, secondary charged 
Figure 1. Cross-sectional view of our modeled cellular matrix depicted by PHITS.
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particles emitted from carbon and oxygen were included in the hydrogen component, though their contributions 
are not so significant. The correlation between recoil proton and carbon ion was considered in simulating the 
nitrogen component, similarly to the boron component. The spectra of produced electrons were separately scored 
as the source term for the photon component. Note that the electron spectra produced from the contamination 
photons in the neutron beam were assumed to be the same as those from photons generated inside the tumor 
because the spectrum of the contamination photons was not evaluated. Using the evaluated source terms, micro-
scopic PHITS simulations were performed to calculate fd,1(zd) and fn,1(zn) for the hydrogen, nitrogen, and photon 
components. The simulation conditions were the same as those used for the boron component calculation except 
for the source locations, where the charged particles were uniformly generated inside the whole central lattice 
because the intra- and extracellular heterogeneity of other dose components was not considered in this study.
For the mixed radiation fields of the boron, hydrogen, nitrogen, and photon components, fd,1(zd) is simply 
obtained from the frequency-mean of the data for each component as written by
λ λ λ λ
λ λ λ λ
=
+ + +
+ + +
γ
γ
γ
f z
f z f z f z f z
( )
( ) ( ) ( ) ( )
,
(12)
d,1 d
B d,1
B
d H d,1
H
d N d,1
N
d d,1 d
B H N
where λB, λH, λN, and λγ are the number of energy-deposition events, i.e., z z/d d,F, for the boron, hydrogen, nitro-
gen, and photon components, respectively, and f z( )d,1
B
d , f z( )d,1
H
d , f z( )d,1
N
d , and 
γf z( )d,1 d  are the PD of zd per event 
for each component. The PD of zn for the mixed radiation fields, fn,1(zn), can also be determined using an equation 
similar to Eq. (12) by replacing fd,1(zd) by fn,1(zn).
It should be mentioned that the cell-nucleus dose for the boron component, znB, is different from the value obtained from the kinetic energy released per unit mass, kerma, of the 10B(n, α)7Li reaction multiplied with the 
neutron fluence and the 10B concentration in tumor (hereafter kerma dose D) due to the heterogeneity of the 
intracellular 10B distribution. To convert the kerma dose of the boron component, DB, to znB, we calculated the ratios between the absorbed doses in cell nucleus for heterogeneous and homogeneous 10B distributions based on 
the PHITS simulation. The evaluated conversion factors, κB, were 0.78 for BPA and 0.51 for BSH. Note that κB 
depends on the distance between the centers of a cell and its nucleus, and they become 0.82 and 0.45 for BPA and 
BSH, respectively, when we assume concentric spheres of a cell and its nucleus. On the other hand, the mean 
absorbed doses in cell nucleus for other components were assumed to be the same as their kerma doses in this 
study because the difference in the material compositions between cell compartments were not considered in our 
simulation. The conversion factor from the total kerma dose, D, to zn, κ, can be obtained from
κ κ= + + + .γD D D D D( )/ (13)B B H N
The numerical value of κ depends on the characteristics of the irradiation field and the 10B compound. Using 
κ and D, Eq. (3) can be rewritten as:
∫κ κ= .
∞
S D S z f z D z( , ) ( ) ( , )d (14)G 0 n n n n n
Consideration of intercellular 10B distribution. It is expected that the larger the variance of the inter-
cellular 10B distribution in tumor cells, the lower the therapeutic efficacy of BNCT. In order to take this effect into 
account, we assumed that a cell population consists of a number of cell groups having a 10B concentration higher 
(or lower) than the population mean value by a factor of x. Under this assumption, Nn, Nc, and Ns should be mul-
tiplied with x, and the conversion factor κ depends on x. Then, the SF for a cell population with kerma dose D, 
SP(D), can be calculated by the summation of the SF of each cell group as written by
∑ κ=S D S x D P( ) ( ( ), ) ,
(15)i
i iP G
where Pi denotes the probability of cells belonging to group i, which satisfies the condition:
∑ =x P 1,
(16)i
i i
where xi is the 10B concentration factor for group i. For continuous intercellular 10B distributions, Eq. (15) can be 
rewritten as:
∫ κ=
∞
S D S x D p x dx( ) ( ( ), ) ( ) , (17)P 0 G
where p(x) denotes the PD of cells having a 10B concentration factor x.
In this study, SP(D) for two different types of the intercellular 10B distributions were analyzed, which are the 
double peak distribution with the same probability, i.e., P1 = P2 = 0.5, x1 = 1 − σ, and x2 = 1 + σ, and the Gaussian 
distribution, i.e., p(x) = σ σ π− −xexp[ ( 1) /2 ]/ 22 2 2 , by changing their standard deviation σ from 0 to 0.6. For 
σ = 0, the probability becomes a single peak with P1 = 1 and x1 = 1, indicating that the 10B concentrations are the 
same for all cells. The double peak distribution represents the situation where the intake of the 10B compounds 
depends on cell cycle; both BPA and BSH are associated with higher rates of boron uptake at G2/M than at G0/G1 
phase21.
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Determination of parameters used in the SMK model. The parameters used in the SMK model, i.e., 
α0, β0, γ0, and rd were determined from the LSq fitting of SF that we previously determined in SCC VII murine 
squamous cell carcinoma22. For experiments, tumor cells were inoculated subcutaneously into the left hind legs 
of syngeneic female C3H/He mice. 10B-carrier solutions with BPA concentrations of 250, 500, and 750 ppm, and 
BSH concentrations of 125, 250, and 375 ppm were prepared, and administrated to the tumor bearing mice in 
a volume of 0.02 ml/g body weight. The mice were irradiated with neutron beam in the OO-0000-F mode of 
KUR32. The neutron and contaminated photon dose rates in the neutron beam were approximately 0.90 and 
0.66 Gy/h, respectively. For both BPA and BSH, the mean 10B concentration in the tumor during irradiation 
was approximately 17, 23, and 26 μg/g with the low, middle, and high ppm, respectively. Note that the actual 10B 
concentrations varied with time after injection very much, and the uncertainties of the mean values are expected 
to be 20–30%. These experiments were approved by the Committee on Safety and Ethical Handling Regulations 
for Laboratory Animal Experiments, Kyoto University, and followed institutional guidelines for the care and use 
of laboratory animals in research. The kerma doses of the experimental data were reevaluated because the kerma 
factors employed in the former evaluation were different from those used in the PHITS simulation. In addition, 
the temporal variation in the 10B concentration during irradiation was also considered in the reevaluation. The 
SF of the tumor cells was measured by a clonogenic cell survival assay. The mice without administrating 10B com-
pounds were also irradiated with the neutron beam as well as a 60Co γ-ray field with dose rate of 2.0 Gy/min to 
obtain the reference data. More details about the experiments have been described previously22.
In the LSq fitting, the chi-square value, χ2, was calculated by
∑χ =





−
Δ




=
S D S D
S D
( ) ( )
( )
,
(18)j
n
j j j j
j j
2
1
,exp ,cal
,exp
2
where Sj,exp(Dj) and ΔSj,exp(Dj) are the measured SF and their uncertainties, respectively, for the irradiation con-
dition j with the kerma dose Dj, Sj,cal is the corresponding SF calculated by our model, and n is the number of 
irradiation conditions, i.e., experimental data points adopted in the fitting. In the calculation of Sj,cal, we employed 
Eq. (15) and set P1 = 1 and x1 = 1, i.e., the heterogeneity of the intercellular 10B distributions being ignored due to 
the difficulty in their evaluation during the measurement. Thus, it is ideal to exclude all experimental data with 
10B administration from the LSq fitting because those data are supposed to be influenced by the heterogeneity. 
However, the uncertainties of the evaluated fitting parameters obtained only from the experimental data without 
10B administration were very large, more than 100%, due to the small number of the data points (only 7 points) 
for four-parameter fitting. We therefore included the experimental data for BSH administration in the LSq fitting 
because of their lower sensitivity to the heterogeneity in comparison to the BPA data, as discussed later.
The procedure for the LSq fitting was as follows. At first, we determined the numerical values of α0, β0, and γ0 
to give the minimum χ2 for each rd for which fd,1(zd) was obtained from the PHITS simulation, based on the 
Levenberg-Marquardt algorithm. Then, the practical best-fit value of rd was determined by searching the smallest 
χ2 among all calculated data. The evaluated parameters are 0.0422 ± 0.0234 Gy−1 for α0, 0.00822 ± 0.00312 Gy−2 
for β0, 4.33 ± 3.74 h−1 for γ0, and 0.24 μm for rd. The accuracy of the fitting was verified by calculating χ2 per 
degree of freedom and R2 for the condition, which are 0.816 and 0.960, respectively. Note that R2 is an adjustment 
for the coefficient of determination, R2, which becomes close to 1 when a model reproduces the data well. It 
should be also mentioned that these parameters were not exactly equal to their best-fit values due to the discrete-
ness of rd. The difference between the evaluated and best-fit values, however, should be trivial due to little depend-
ence of χ2 on rd around 0.24 μm.
Results and Discussion
PD of zd and zn. Figure 2 shows the cross-sectional views of calculated absorbed doses per Monte Carlo 
history for each dose component. For the boron component (panel A), the data for the cytoplasmic localization 
source are depicted. Note that these simulations started with the production of charged particles, so that neutron 
and photon motions were not simulated. It is evident that while the absorbed doses are concentrated in the cen-
tral cell or its neighboring cells for the boron and nitrogen components, they are widely spread for the photon 
component due to longer ranges of secondary electrons. For the hydrogen component, most particles stop very 
close to the central cell similarly to the nitrogen component, but occasionally travel through several cells because 
Figure 2. Cross-sectional views of calculated absorbed doses per source generation for each dose component.
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some protons recoiled by high-energy neutrons have an energy in the order of MeV. Note that the range of 1 MeV 
proton in water is approximately 24 μm.
Figure 3 shows the zdfd,1(zd) calculated for each dose component and for some experimental conditions. The 
data for the experimental conditions with higher concentrations of 10B compounds are not shown because the 
calculated PD does not much depend on the 10B concentration. The domain radius, rd, was set to 0.24 μm as its 
evaluated value in this calculation. The upper axis denotes the corresponding lineal energy, y, which is frequently 
compared with LET. In general, the calculated zdfd,1(zd) is shifted to higher specific energies with an increase in 
LET of the primary contributing particle for each component. Two broad peaks are observed in the data for the 
boron component, which are attributed to the contributions from δ-rays and primary ions, respectively. The sharp 
peak observed in the data for the photon component around 2 Gy is originated from the production of an Auger 
electron.
Figure 4 shows the calculated znfn,1(zn) for each dose component and for some experimental conditions. 
Unlike zdfd,1(zd) shown in Fig. 3, the znfn,1(zn) calculated for BPA and BSH is apparently different from each other; 
a sudden decrease of znfn,1(zn) around 0.5 Gy is observed only in the data for BSH. This is because Li ions pro-
duced at the cell surface can reach but not penetrate its cell nucleus due to their short range of approximately 4 
μm. Note that the events with the highest specific energy, approximately 2 Gy, occur when an α particle or a Li ion 
penetrates at the center of a cell nucleus. The gap observed in the data for nitrogen component around 0.06 Gy is 
attributed to the 14N(n,p)14C reaction occurring in cell nucleus because such events deposit at least 0.042 MeV, the 
energy of recoil carbon ion, in cell nucleus.
Figure 5 shows z f z z( , )n n n n  for some experimental conditions calculated by numerically solving Eqs (5) and 
(6). The shapes of z f z z( , )n n n n  are similar to those of the corresponding znfn,1(zn) for lower zn, while they become 
closer to the Gaussian distribution with increasing zn. It is evident from the graphs that the administration of 10B 
Figure 3. Calculated zdfd,1(zd) for each dose component (left) and some experimental conditions (right). The 
upper axis denotes the corresponding lineal energy, y, which is frequently compared with LET.
Figure 4. Calculated znfn,1(zn) for each dose component (left) and some experimental conditions (right).
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enlarges the variance of the PD even for the highest zn, indicating higher intercellular dose heterogeneity. 
Noteworthy is that the intercellular dose heterogeneity becomes even higher when the intercellular 10B distribu-
tion is considered.
Surviving fraction. Figure 6 shows the measured and calculated SF for the tumor cells with administrated 
BPA (pane1 A), BSH (pane1 B) or without 10B compound (panel C), plotted as a function of the total kerma dose 
in the tumor including the boron component. The calculated data were obtained from Eq. (15) by setting P1 = 1 
and x1 = 1, i.e., the heterogeneity of the intercellular 10B distribution was not considered in this calculation. The 
agreements between the measured and calculated SF are quite satisfactory for BSH administrated and without 10B 
compound cases, which were used in the LSq fitting. On the other hand, our calculation underestimates the 
experimental data for BPA cases particularly at higher 10B concentrations. In addition, the dependence of the SF 
on the 10B concentration is less significant in our calculated data. These disagreements are probably attributable 
to the ignorance of the heterogeneity of the intercellular 10B distribution as discussed later. At the same kerma 
dose, the calculated SF for BPA cases are smaller than those for BSH cases because of the larger conversion factor 
from the kerma dose D to the mean cell-nucleus dose zn, owing to cell permeability of BPA.
Except for the photon data, the β terms of the measured SF shown in Fig. 6 are very close to 0 or even negative, 
and our calculation can reproduce this tendency very well even using the same β0 parameter for all radiations. 
This is predominantly because our calculation considered the intercellular dose heterogeneity, which increases 
the SF for high-dose and high-LET irradiations. In addition, consideration of the dose rate effect also reduces β 
particularly for the data with longer irradiation time as indicated by Eq. (10). For example, the irradiation time 
T is roughly 9 hours and G calculated by Eq. (10) is approximately 0.05 for the highest-dose neutron beam irra-
diation without 10B compound. For quantitative discussion, Fig. 7 shows the SF calculated without considering 
the intercellular dose heterogeneity or the dose rate effect, in comparison with the corresponding data with full 
Figure 5. Calculated z f z z( , )n n n n  for some experimental conditions obtained by numerically solving Eqs (5) 
and (6)
Figure 6. Measured and calculated SF for SCC VII squamous cell carcinomas administrated with (A) BPA,  
(B) BSH, and (C) without 10B compound, plotted as a function of total kerma dose in the tumor including the 
boron component. Those cells were inoculated into mice and irradiated by neutron beam of KUR except for the 
60Co γ-ray data shown in Panel (C). The heterogeneity of the intercellular 10B distribution is not considered in 
this calculation.
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consideration. It is evident from the graph that the consideration of the intercellular dose heterogeneity increases 
the SF very much particularly for 10B administrated cases because of their larger heterogeneity. On the other hand, 
the dose rate effect has little influence on the calculated SF for the 10B administrated cases because of two reasons; 
it becomes less significant for higher dose rates, and it changes only quadratic coefficient of the LQ relationship 
as written in Eq. (9), while those data are predominantly determined by the linear coefficient. These tendencies 
indicate that the consideration of the intercellular dose heterogeneity is indispensable to the estimate of the thera-
peutic effect of BNCT, while that of the dose rate effect is desirable in the estimate of normal tissue complications 
with lower 10B concentration.
Figures 8 and 9 show the SF calculated for 250 ppm BPA and 125 ppm BSH, respectively, assuming that the 
intercellular heterogeneity of 10B concentrations can follow the Gaussian or double-peak distributions with the 
standard deviation of σ. The corresponding experimental data including those for other 10B concentrations are 
also shown in the figures. The data calculated for other 10B concentrations are nearly comparable to the plotted 
data with the same σ, similarly to the data shown in Fig. 6. In general, the calculated SF increases with increasing 
σ particularly for the BPA data at higher doses because the intercellular dose heterogeneity becomes greater. The 
BSH data are less sensitive to σ than the BPA data because a large fraction of BSH localizes in the extracellular 
region whose 10B concentration is not affected by σ. The SF calculated for the same σ assuming the Gaussian and 
double-peak distributions agrees fairly well with each other. Considering the quite different shapes between the 
Gaussian and double-peak distributions, this tendency indicates that the intercellular 10B distribution can roughly 
be represented only by their standard deviation, irrespective of the form of the distribution.
As aforementioned, our calculation without considering the intercellular 10B distribution underestimates the 
measured SF of cells administrated with BPA particularly at higher concentrations. In addition, the calculated 
Figure 7. Calculated SF without considering the intercellular dose heterogeneity (IDH) or the dose rate effect 
(DRE), in comparison with the corresponding data with full consideration. Corresponding experimental data 
are also plotted in the graph.
Figure 8. Calculated SF for 250 ppm BPA (17 μg/g) obtained under assumption that the intercellular 
heterogeneity of 10B concentrations can be expressed by the (A) Gaussian or (B) double-peak distributions with 
the standard deviation of σ. The corresponding experimental data including those for other 10B concentrations 
are also shown in the graph.
www.nature.com/scientificreports/
1 0SCiENtifiC REPORTS |  (2018) 8:988  | DOI:10.1038/s41598-017-18871-0
SF for higher BSH concentrations is also smaller than the corresponding experimental data to some extent. 
These tendencies can be explained under assumption that σ of the intercellular 10B distribution increases with an 
increase in its mean value, since the calculated data for higher σ agree with the experimental data at the higher 
ppm, as shown in Fig. 8. This assumption can be interpreted biologically if the maximum capacity for intake of 
10B compounds would vary with each cell, such that some cells having less capacity might not incorporate suffi-
cient 10B compounds than others when 10B compounds are administrated at a higher concentration. However, the 
relation between the variance and mean of the intercellular 10B distribution has not been investigated, warranting 
further studies to clarify this issue. It should be mentioned that cell cycle plays a very important role in determin-
ing the intercellular 10B distribution21, and thus, the consideration of the cell cycle dependence of the radiation 
sensitivity is also desirable in our model for more precise estimation of SF.
RBE and CBE. Figure 10 shows the RBE or CBE calculated for each dose component and for some experi-
mental conditions as a function of the total kerma dose in the tumor including the boron component. The hetero-
geneity of the intercellular 10B distribution was not considered in this calculation. CBE for an ideal 10B compound 
that can be homogeneously distributed inside cell including its nucleus is also drawn in the left panel. As for the 
terminological distinction between RBE and CBE, the latter is used only for expressing the biological effectiveness 
of the boron dose component in this paper because the contributions from other dose components should be 
excluded in the estimate of its numerical value, i.e. the biological effectiveness directly deduced from the experi-
mental conditions is not CBE even for 10B administrated cases.
Figure 9. Calculated SF for 125 ppm BSH (17 μg/g) obtained under assumption that the intercellular 
heterogeneity of 10B concentrations can be expressed by the (A) Gaussian or (B) double-peak distributions with 
the standard deviation of σ. The corresponding experimental data including those for other 10B concentrations 
are also shown in the graph.
Figure 10. Calculated RBE or CBE for each dose component (left) and for some experimental conditions 
(right) as a function of the total kerma dose in tumor including the boron component. CBE for an ideal 10B 
compound that can be homogeneously distributed inside cell is also drawn in the left panel.
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These data were obtained from the equation:
α α β
β
=


− + − 
γ γ
S
D
RBE or CBE
4 ln( )
2
,
(19)
2
0
0
where S is the SF for each dose component or experimental condition for the kerma dose D, and αγ is the α term 
of the SF for the 60Co γ-ray irradiation, which was evaluated to be 0.0634 Gy−1 from Eq. (1). This equation implies 
that the SF for the γ-ray irradiation can be simply expressed by the LQ model without considering the stochastic 
nature of zn. Experimentally determined RBE shown in the right panel of Fig. 10 were also obtained from Eq. (19), 
considering the dose rate effect.
It is evident from the graphs that the calculated RBE and CBE decrease with increasing the kerma dose 
because the β term is not clearly observed in the calculated SF except for γ-ray irradiation due to the greater 
intercellular dose heterogeneity as discussed above. The dose rate effect also reduces the RBE and CBE for the 
experimental conditions. The CBE for BPA and BSH was smaller than that for the ideal 10B compound by factors 
of approximately 1.2 and 1.8, respectively. This tendency is attributed to κB < 1 for both BPA and BSH owing to 
their impermeability of cell nucleus. Thus, the therapeutic effect of BNCT would be much higher if a 10B com-
pound permeating cell nucleus could be developed. The lower RBE for the experimental condition without 10B 
is due to the longer irradiation time as well as the higher dose fraction of the photon component; approximately 
40% of the dose derived from the photon component when 10B was absent, whereas the fractions were generally 
less than 10% when 10B was administrated.
Table 1 summarizes the calculated RBE or CBE at certain levels of SF – 50%, 10%, and 1% – for each dose 
component and experimental condition. As expected from Fig. 10, RBE and CBE decrease with decreasing SF. 
The RBE values of the experimental conditions for BPA and BSH cases are higher than the corresponding CBE 
values of the boron components, due to the existence of the synergetic effect in the experimental conditions. It 
should be mentioned that the kerma dose in the blood, which can be estimated from the 10B concentration in the 
blood instead of tumor, is generally calculated as the physical dose in the BNCT treatment planning. Thus, the 
calculated CBE data should be multiplied with the ratio of the 10B concentrations in tumor and blood when they 
are used for estimating the therapeutic effect.
Figure 11 shows the calculated RBE for 250 ppm BPA and 125 ppm BSH considering the intercellular hetero-
geneity in 10B distributions. The Gaussian distributions with the standard deviation σ were assumed in the calcu-
lation. The corresponding experimental data including those for other 10B concentrations are also shown in the 
graphs. As expected from Figs 8 and 9, the calculated RBE decreases more dramatically with increasing the kerma 
dose at higher σ, particularly when BPA is administered. This tendency suggests that reduction of the variance of 
the intercellular heterogeneity in 10B distributions is important to maintain the higher therapeutic efficacy of high 
dose irradiation, particularly for BPA.
RBE-weighted dose and photon-isoeffective dose. Figure 12 shows the calculated RBE-weighted 
doses and photon-isoeffective doses for 250 ppm BPA and 125 ppm BSH. As aforementioned, the term of 
“RBE-weighted dose” used for BNCT implies that RBE or CBE is independent of dose and dose rate. In this study, 
RBE and CBE at 10% SF, i.e., RBE10 and CBE10 shown in Table 1, were adopted for estimating the RBE-weighted 
doses, and are thus proportional to the dose. In contrast, the photon-isoeffective doses were estimated from the 
dose-dependent RBE and CBE as shown in Fig. 10. In both cases, we evaluated the data with or without consider-
ing the synergetic effect, i.e., the total dose multiplied with CBE for the experimental condition, or the sum of the 
doses for each component multiplied with their own RBE or CBE. The RBE-weighted doses that were estimated 
from the RBE and CBE values adopted in the computational dosimetry system named JCDS1,34 are also drawn 
RBE50 or CBE50 RBE10 or CBE10 RBE1 or CBE1
Dose component
Boron (BPA) 5.49 3.60 2.74
Boron (BSH) 3.55 2.33 1.76
Hydrogen 3.95 2.72 2.16
Nitrogen 4.07 2.78 2.21
Boron (ideal) 6.56 4.30 3.25
Experimental condition
BPA 250 ppm 5.79 3.74 2.81
BPA 500 ppm 5.80 3.75 2.82
BPA 750 ppm 5.79 3.75 2.81
BSH 125 ppm 4.09 2.65 1.99
BSH 250 ppm 4.05 2.62 1.97
BSH 375 ppm 4.02 2.60 1.96
without 10B 2.59 1.69 1.25
Table 1. RBE or CBE calculated at certain levels of SF – 50%, 10%, and 1% – for each dose component and 
experimental condition.
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in the graphs, where CBE for the boron component were 3.8 and 2.5 for BPA and BSH, respectively, and RBE for 
both hydrogen and nitrogen components were 2.5. Note that JCDS was applied to the BNCT treatment planning 
of clinical trials conducted in Japan Atomic Energy Agency (JAEA).
The photon-isoeffective dose is higher than RBE-weighted doses at lower kerma dose, whereas the reverse is 
true at higher kerma dose. The crossing point indicates the kerma dose to give 10% SF. The difference between the 
RBE-weighted and photon-isoeffective doses becomes larger as the kerma dose increases. Thus, the dose depend-
ence of RBE and CBE should be taken into account in the BNCT treatment planning particularly for high dose 
irradiation, otherwise the therapeutic effect in comparison to photon therapy would be overestimated. This ten-
dency confirms the conclusion previously obtained from other studies14,15, where the photon-isoeffective doses 
derived from tumor control and normal tissue complication probabilities should be lower than the corresponding 
RBE-weighted doses, from the viewpoint of microdosimetry. The consideration of the synergetic effect enlarges 
both RBE-weighted and photon-isoeffective doses because RBE for the experimental conditions is higher than 
CBE or RBE for each dose component, as shown in Table 1.
Figure 11. Calculated RBE for (A) 250 ppm BPA and (B) 125 ppm BSH considering the intercellular 
heterogeneity in 10B distributions. The Gaussian distributions with the standard deviation σ were assumed in the 
calculation. The corresponding experimental data including those for other 10B concentrations are also shown 
in the graphs.
Figure 12. Calculated RBE-weighted doses and photon-isoeffective (P.I.) doses for (A) 250 ppm BPA and  
(B) 125 ppm BSH. Red and blue lines denote the data calculated with and without considering the synergetic 
effect (S.E.), respectively. The RBE-weighted doses estimated from the RBE and CBE values adopted in JCDS are 
also drawn in the graphs.
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Conclusions
We have here developed a model for estimating the biological effectiveness of BNCT considering the intra- and 
intercellular heterogeneity in 10B distribution on the basis of the SMK model. The synergetic effect of mixed radi-
ation fields can also be taken into account in the model similarly to other cell inactivation models proposed for 
BNCT14. Four free parameters exist in the model, and in this study, their numerical values were determined from 
the LSq fitting of the SF of tumor cells obtained from our previously reported in vivo/in vitro measurements using 
mice administrated with BPA or BSH. Our model can satisfactorily reproduce the measured SF as well as their 
associated RBE and CBE in various experimental conditions. Our model quantitatively verified that the consider-
ations of the synergetic effect and the dose dependence of RBE and CBE are very important in the estimate of the 
therapeutic effect of BNCT. The model is planned to be implemented into a research version of our developing 
treatment planning system, Tsukuba plan35, in the near future. For that purpose, the SMK model parameters not 
only for tumor but also for normal tissue cells must be evaluated because the estimate of normal tissue complica-
tions is as important as that of the therapeutic effect in the treatment planning, particularly in the determination 
of irradiation time. Note that the applications of our model to the estimate of normal tissue complications are 
limited to those attributable to cell inactivation, such as acute skin reactions36.
A unique feature of our model is that it can predict the biological effectiveness of newly developed 10B com-
pounds based on their intra- and intercellular heterogeneity. For example, our model suggests that the realiza-
tion of an ideal 10B compound that is homogeneously distributed in the whole cell would enlarge the biological 
effectiveness by factors of approximately 1.2 and 1.8 in comparison to those of BPA and BSH, respectively. The 
intercellular homogeneity is also expected to be important to keep the higher therapeutic effect of high dose irra-
diation, otherwise CBE suddenly drops with increasing dose. Owing to this feature, our model can play important 
roles not only in the treatment planning but also in developing new 10B compounds used for future BNCT. More 
precise measurement of the intra- and intercellular 10B distributions is the key issue for applying our model to the 
drug discovery research.
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